Measuring prognosis in chronic myeloid leukemia: what's new?

被引:4
作者
Breccia, Massimo [1 ]
Efficace, Fabio [2 ]
Scalzulli, Emilia [1 ]
Ciotti, Giulia [1 ]
Maestrini, Giacomo [1 ]
Colafigli, Gioia [1 ]
Martelli, Maurizio [1 ]
机构
[1] Sapienza Univ, Dept Translat & Precis Med, Az Policlin Umberto 1, Rome, Italy
[2] Italian Grp Adult Hematol Dis GIMEMA, Data Ctr & Hlth Outcomes Res Unit, Rome, Italy
关键词
Chronic myeloid leukemia; prognostic scores; chromosome abnormalities; prognosis; survival; CHRONIC MYELOGENOUS LEUKEMIA; PATIENT-REPORTED OUTCOMES; LONG-TERM SURVIVAL; ADDITIONAL CHROMOSOMAL-ABNORMALITIES; BONE-MARROW-TRANSPLANTATION; TYROSINE KINASE INHIBITORS; QUALITY-OF-LIFE; CHRONIC PHASE; PHILADELPHIA-CHROMOSOME; CYTOGENETIC RESPONSE;
D O I
10.1080/17474086.2021.1938534
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: The outcome of chronic myeloid leukemia (CML) patients in chronic phase has changed after the introduction of tyrosine kinase inhibitors (TKIs). The life expectancy is actually similar to that of the general population. Prognostic stratification at baseline is part of a patient-centered approach to decide the best therapeutic approach. Areas covered: In this review, the current prognostic factors examined at baseline are detailed and the meaning is explained. A broad research on Medline, Embase and archives from EHA and ASH congresses, was performed. Prognostic factors have been divided into patient-related (age, gender, comorbidities, etc.) and disease-related (additional cytogenetic abnormalities, type of transcript, etc). New information about genomic data and the potential role of patient-reported outcomes is also discussed. Expert Opinion: Prognostic factors at baseline should be considered to evaluate the long-term probability of disease-related death, the possible toxicity, and the projected long-term overall survival. The genomic assessment would provide the basis for a genomic-based risk and help in oriented decision-making process.
引用
收藏
页码:577 / 585
页数:9
相关论文
共 50 条
[21]   Human immunodeficiency virus infection and chronic myeloid leukemia [J].
Patel, Moosa ;
Philip, Vinitha ;
Fazel, Fatima ;
Lakha, Atul ;
Vorog, Alexander ;
Ali, Nazeer ;
Karstaedt, Alan ;
Pather, Sugeshni .
LEUKEMIA RESEARCH, 2012, 36 (11) :1334-1338
[22]   Outcome prediction of chronic myeloid leukemia (CML) in children [J].
Leung, Wing-Yan ;
Cheuk, Daniel Ka-Leung ;
Cheng, Frankie Wai-Tsoi ;
Leung, Alex Wing-Kwan ;
Chiu, Ka-Ho ;
Ho, Karin Kar-Huen ;
Li, Chak-Ho ;
Chan, Godfrey Chi-Fung .
ANNALS OF HEMATOLOGY, 2022, 101 (08) :1677-1688
[23]   History of chronic myeloid leukemia: A paradigm in the treatment of cancer [J].
Gonon-Demoulian, R. ;
Goldman, J. M. ;
Nicolini, F. E. .
BULLETIN DU CANCER, 2014, 101 (01) :56-67
[24]   Long-term Treatment of Chronic Myeloid Leukemia [J].
Yavuz, Akif Selim .
UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, 2011, 21 (02) :10-17
[25]   On the road to treatment-free remission in chronic myeloid leukemia: what about 'the others'? [J].
Stagno, Fabio ;
Breccia, Massimo ;
Di Raimondo, Francesco .
EXPERT REVIEW OF ANTICANCER THERAPY, 2020, 20 (12) :1075-1081
[26]   Genetic Biomarkers in Chronic Myeloid Leukemia: What Have We Learned So Far? [J].
Abdulmawjood, Bilal ;
Costa, Beatriz ;
Roma-Rodrigues, Catarina ;
Baptista, Pedro V. ;
Fernandes, Alexandra R. .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (22)
[27]   Chronic Myeloid Leukemia Prognosis and Therapy: Criticisms and Perspectives [J].
Russo, Domenico ;
Garcia-Gutierrez, Jose Valentin ;
Soverini, Simona ;
Baccarani, Michele .
JOURNAL OF CLINICAL MEDICINE, 2020, 9 (06)
[28]   Emerging Therapies in Chronic Myeloid Leukemia [J].
Gora-Tybor, J. .
CURRENT CANCER DRUG TARGETS, 2012, 12 (05) :458-470
[29]   Do we need more drugs for chronic myeloid leukemia? [J].
Holyoake, Tessa L. ;
Helgason, G. Vignir .
IMMUNOLOGICAL REVIEWS, 2015, 263 (01) :106-123
[30]   Prognostic importance of additional cytogenetic anomalies in chronic myeloid leukemia [J].
Bozkurt, Sureyya ;
Uz, Burak ;
Buyukasik, Yahya ;
Bektas, Ozlen ;
Inanc, Ayten ;
Goker, Hakan ;
Kansu, Emin .
MEDICAL ONCOLOGY, 2013, 30 (01)